Merck & Co., Inc.
Net buyer this quarter
$526M
13
+$12.8M
99.8%
Holdings
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026 | |||||
 PSNL | $188M | 35.75% | 13.20% | Not reported | Q4 2024 |
 MRNA | $162M | 30.71% | 0.58% | Not reported | Q4 2024 |
 KYMR | $88.5M | 16.82% | 0.93% | Not reported | Q4 2024 |
 AKTS | $30.7M | 5.83% | 1.78% | Not reported | Q1 2026 |
 EIKN | $21.7M | 4.13% | 3.08% | Not reported | Q1 2026 |
 TRDA | $12.8M | 2.43% | 4.47% | New | Q2 2026 |
 STRO | $9.04M | 1.72% | 1.64% | Not reported | Q4 2024 |
 ALEC | $7.13M | 1.35% | 3.18% | Not reported | Q4 2024 |
 EVAX | $3.76M | 0.71% | 0.29% | Not reported | Q4 2024 |
 VRDN | $1.72M | 0.33% | 0.08% | Not reported | Q4 2024 |
 XLO | $1.02M | 0.19% | 1.61% | Not reported | Q4 2024 |
 HURA | $45.5K | 0.01% | 0.03% | Not reported | Q2 2025 |
 NEUP | $43.8K | 0.01% | 0.19% | Not reported | Q4 2024 |
| Q1 2026 | |||||
| MRNA | $117M | 33.56% | 0.58% | Not reported | Q4 2024 |
| PSNL | $89.5M | 25.60% | 13.42% | Not reported | Q4 2024 |
| KYMR | $64.3M | 18.40% | 0.94% | Not reported | Q4 2024 |
| EIKN | $17.6M | 5.05% | 3.08% | New | Q1 2026 |
| AKTS | $17M | 4.88% | 1.78% | New | Q1 2026 |
| ALEC | $7.62M | 2.18% | 3.19% | Not reported | Q4 2024 |
| STRO | $6.78M | 1.94% | 1.64% | Not reported | Q4 2024 |
| EVAX | $4.52M | 1.29% | 0.29% | Not reported | Q4 2024 |
| VRDN | $1.83M | 0.52% | 0.09% | Not reported | Q4 2024 |
| XLO | $891K | 0.26% | 1.83% | 0.0% | Q4 2024 |
| CARM | $47.9K | 0.01% | 3.52% | Not reported | Q4 2024 |
| NEUP | $40.8K | 0.01% | 0.19% | Not reported | Q4 2024 |
| HURA | $34.8K | 0.01% | 0.03% | +39.4% | Q2 2025 |
| Q4 2025 | |||||
| PSNL | $112M | 40.47% | 13.71% | Not reported | Q4 2024 |
| MRNA | $68.1M | 24.64% | 0.59% | Not reported | Q4 2024 |
| KYMR | $60.1M | 21.75% | 0.95% | Not reported | Q4 2024 |
| EVAX | $5.79M | 2.10% | 0.29% | Not reported | Q4 2024 |
| ALEC | $5.53M | 2.00% | 3.21% | Not reported | Q4 2024 |
| STRO | $3.15M | 1.14% | 3.17% | 0.0% | Q4 2024 |
| VRDN | $2.91M | 1.05% | 0.09% | Not reported | Q4 2024 |
| XLO | $950K | 0.34% | 32.75% | Not reported | Q4 2024 |
| CARM | $63.3K | 0.02% | 3.52% | Not reported | Q4 2024 |
| NEUP | $38.9K | 0.01% | 0.19% | Not reported | Q4 2024 |
| HURA | $10.6K | 0.00% | 0.02% | Not reported | Q2 2025 |
| Q3 2025 | |||||
| PSNL | $91.6M | 40.16% | 15.83% | Not reported | Q4 2024 |
| MRNA | $59.6M | 26.15% | 0.59% | Not reported | Q4 2024 |
| KYMR | $43.7M | 19.17% | 1.08% | Not reported | Q4 2024 |
| ALEC | $10.5M | 4.60% | 3.30% | Not reported | Q4 2024 |
| EVAX | $4.57M | 2.00% | 8.66% | Not reported | Q4 2024 |
| STRO | $2.37M | 1.04% | 3.20% | Not reported | Q4 2024 |
| VRDN | $2.02M | 0.88% | 0.11% | Not reported | Q4 2024 |
| LVTX | $1.79M | 0.79% | 4.37% | Not reported | Q4 2024 |
| XLO | $1.25M | 0.55% | 2.86% | Not reported | Q4 2024 |
| CARM | $404K | 0.18% | 3.53% | Not reported | Q4 2024 |
| NEUP | $118K | 0.05% | 0.43% | Not reported | Q4 2024 |
| HURA | $34.6K | 0.02% | 0.03% | Not reported | Q2 2025 |